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AnakinraFirst described in 1971, adult-onset Still's disease (AOSD) is a rare multisystemic disorder considered as a complex
(multigenic) autoinﬂammatory syndrome.
A genetic backgroundwould confer susceptibility to the development of autoinﬂammatory reactions to environ-
mental triggers. Macrophage and neutrophil activation is a hallmark of AOSD which can lead to a reactive
hemophagocytic lymphohistiocytosis. As in the latter disease, the cytotoxic function of natural killer cells is
decreased in patients with active AOSD. IL-18 and IL-1β, two proinﬂammatory cytokines processed through
the inﬂammasome machinery, are key factors in the pathogenesis of AOSD; they cause IL-6 and Th1 cytokine
secretion as well as NK cell dysregulation leading to macrophage activation.
The clinico-biological picture of AOSD usually includes high spiking fever with joint symptoms, evanescent skin
rash, sore throat, striking neutrophilic leukocytosis, hyperferritinemia with collapsed glycosylated ferritin
(b20%), and abnormal liver function tests.
According to the clinical presentation of the disease at diagnosis, two AOSD phenotypesmay be distinguished:
i) a highly symptomatic, systemic and feverish one, which would evolve into a systemic (mono- or polycyclic)
pattern; ii) a more indolent one with arthritis in the foreground and poor systemic symptomatology, which
would evolve into a chronic articular pattern.
Steroid- and methotrexate-refractory AOSD cases beneﬁt now from recent insights into autoinﬂammatory disor-
ders: anakinra seems to be an efﬁcient, well tolerated, steroid-sparing treatment in systemic patterns; tocilizumab
seems efﬁcient in AOSD with active arthritis and systemic symptoms while TNFα-blockers could be interesting in
chronic polyarticular refractory AOSD.
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In 1897, Sir George Frederick Still described 22 children with symp-
toms consistent with the current systemic onset of juvenile idiopathic
arthritis (SOJIA) [1]. One year before, the ﬁrst case of an adult patient
exhibiting the same symptoms had been reported in The Lancet. Then,
numerous cases of patients suffering from high spiking fever,
polyarthritis, lymphadenopathy, evanescent rash, sore throat and a
striking leukocytosis of unknown origin were described and grouped
in Europe under ‘Wissler–Fanconi syndrome’ [2]. In 1971, EG Bywaters
described the ﬁrst series of 14 adults with the same symptoms as
those seen in the pediatric Still's disease, deﬁning thus the adult-onset
Still's disease (AOSD) [3]. Today, AOSD remains a rare multisystemic
autoinﬂammatory disorder of unknown etiology and difﬁcult diagnosis
because of the wide range of differential diagnoses. Nonetheless, an
early diagnosis may improve the prognosis [4]; this calls for a better
knowledge of this complex disease.
The evolutive and prognostic patterns of AOSD have been better
deﬁned recently and the therapeutic strategies have beneﬁted from
progresses in the understanding of monogenic autoinﬂammatory
diseases. This review will focus on these two topics.
2. Epidemiology and pathophysiology
2.1. Epidemiology
Robust epidemiologic data on AOSD are lacking. The disease occurs
worldwide and affects usually young adults (themedian age at diagnosis
is circa 36 years [4,5]) though onsetswere described up to 83 years [6,7].
Its incidence has been estimated at 0.16 (per 100,000 persons) in France
[8], 0.22 in Japan [9], and 0.4 in Norway [10]. In the Japanese and the
European populations, the reported prevalence rates range from 1 to
34 cases per 1 million persons. In rheumatologic case series, women
seem to be more often affected than men; they represent up to 70% of
the patients [5,11,12]; however, in internal medicine case series,
women represent only 45 to 53% of the patients [4,13]. The hormonal
inﬂuences are poorly understood; nevertheless, the second trimester of
pregnancy and the postpartum period would increase the risk of disease
recurrence [14].
2.2. Genetics
Although no familial trend has been reported in AOSD, some studies
have reported associations with HLA antigens. HLA-Bw35 was the ﬁrst
identiﬁed as a susceptibility antigen and associated with a mild self-limiting pattern of the disease [15]. HLA-DR4was foundmore prevalent
in 29 AOSD cases vs. healthy controls and HLA-DRw6 was associated
with the occurrence of proximal arthralgia [16]. In a survey on 55
patients from Canada, Pouchot et al. described a strong association
between AOSD and HLA-B17, -B18, -B35, and -DR2 [13]. In Japan,
HLA-DRB1*1501 (DR2) and HLA-DRB1*1201 (DR5) have been found
associated with chronic AOSD whereas HLA-DQB1*0602 (DQ1) has
been found associated with both chronic and systemic AOSD [17].
Finally, a Korean study compared 47 AOSD cases with 144 healthy
controls focusing on the HLA-DRB1 genotype; AOSD patients had
more frequentlyHLA-DRB1*12 and -DRB1*15, and less frequently HLA-
DRB1*04. Patients with the monocyclic systemic pattern had more fre-
quent HLA-DRB1*14 [18]. In summary, no consistent results have been
obtained from association studies between AOSD and HLA loci. This
may result either from a real absence of association or from a wide
heterogeneity of such an association between different ethnic groups.
More recently, a Japanese study evaluating polymorphisms in the in-
terleukin (IL)-18 gene discovered that the frequency of diplotype con-
ﬁguration S01/S01 was signiﬁcantly higher in AOSD patients than in
healthy controls [19]. Also, a functional promoter polymorphism in
themacrophagemigration inhibitory factor (MIF) gene seemed to inﬂu-
ence plasma MIF levels in AOSD and may contribute to disease suscep-
tibility [20]. Furthermore, SOJIA has been associated with a functional
polymorphism in the IL-6 gene promoter that affects gene transcription
and, therefore, IL-6 levels [21]. Conversely, in 96 Korean patients, no
mutation in the MEFV gene (responsible for familial Mediterranean
fever) was associated with the development of AOSD [22].2.3. Triggering factors
So far, the etiology of AOSD remains unknown. An infectious eti-
ology has been suspected because of similar clinical presentations
between AOSD and established infectious syndromes; e.g., abrupt
onset, high fever, generalized adenopathy, splenomegaly, and leuko-
cytosis. Many microorganisms were thus searched for. A number of
viruses (rubella, measles, Echovirus 7, Coxsackievirus B4, Cytomega-
lovirus, Epstein–Barr virus, Human herpesvirus 6, Parainﬂuenza, In-
ﬂuenza A, Adenovirus, hepatitis B and C, and Parvovirus B19)
[23–26] and bacteria (Mycoplasma pneumonia, Chlamydia pneumo-
nia, Yersinia enterocolitica, Brucella abortus, and Borrelia burgdorferi)
[27,28] were isolated in patients with AOSD but their responsibility
has never been clearly established. It is proposed that infection can
trigger an interplay between host genetic factors, autoimmunity
mechanisms, and pathogenic antigens, leading ultimately to the dis-
ease pathogenesis.
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disease associated with malignancies including solid cancer (60% of
the cases, mainly breast and lung) and hematological malignancies
(40%,mainlymalignant lymphoma) [29]. Thus, it is probable thatmalig-
nancies can also trigger the onset of AOSD as already described in
hemophagocytic lymphohistiocytosis [30].
2.4. Immunopathogenesis
The recent improvements in the understanding of monogenic
autoinﬂammatory diseases provided valuable evidence about the
immunopathogenetic mechanisms of AOSD (Fig. 1).
2.4.1. Innate immunity
2.4.1.1. Activation of innate immune cells. Neutrophil and macrophage
activation is a hallmark of AOSD. CXCL 8 (ex-IL-8) levels were found in-
creased in AOSD patients (vs. healthy controls) but did not correlate
with the disease activity [29]. This chemokine mobilizes and activates
neutrophils at the site of inﬂammation and is associatedwith the persis-
tence of chronic articular AOSD [32]. Furthermore, the neutrophil acti-
vation marker CD64 (FcγR1) was found upregulated and correlated
with active AOSD [33].
Many markers reﬂecting macrophage activation correlated with the
activity of the disease. Macrophage-colony stimulating factor (M-CSF)
and interferon (IFN) γ are both increased in the serum of AOSD patients
[31,34,35]. Also, calprotectin, MIF, and intracellular adhesion molecule-1
(ICAM-1) may serve as useful markers for AOSD activity and severity
[36–38]. The disease is also strongly associated with the reactive
hemophagocytic lymphohistiocytosis (RHL, previously termed
macrophage-activation syndrome), which is a life-threatening com-
plication [39–42]. In AOSD as in RHL, recent ﬁndings argue for a potentFig. 1. Proposed pathophysiological model for adult-onset Still's disease. Danger signals (patho
inﬂammasome (NLRP3*), which triggers the activation and secretion of proinﬂammatory cytok
the same time, upon Toll-like receptor (TLR)-7 activation, dendritic cells induce Th17 respons
production, through IL-1 receptor, in an autocrineway. IL-6 is responsible for the liver synthesi
tion, which in turn increases macrophage activation. In AOSD, NK cells are abnormal, their cy
hemophagocytic lymphohistiocytosis, a life-threatening complication of AOSD.immunomodulatory role of high ferritin levels in both steady AOSD and
RHL [43–45].
2.4.1.2. Natural killer (NK) cells. The levels and cytotoxic functions of NK
cells and NKT cells were decreased in AOSD (vs. no disease or inactive
AOSD) [46,47]. These parameters correlate with the disease control;
they improve during efﬁcient treatment of AOSD. Pro-inﬂammatory
cytokines, mostly IL-18, were suspected to cause NK cell priming to
secrete IFNγ and to be associated with familial hemophagocytic
lymphohistiocytosis susceptibility [48–50]. Furthermore, the impairment
of NK cell cytotoxicity was associated with familial hemophagocytic
lymphohistiocytosis, the most frequent form being secondary to perforin
deﬁciency [30,51]. Perforin is a pivotal effector molecule for cytotoxicity
and is present in the granules of cytotoxic T cells andNKcells. A decreased
perforin expressionwas reported in SOJIA [52]. Given the high association
between RHL and AOSD, these disorders might share a common ﬁnal
pathway of abnormal IL-18 secretion and abnormal NK cell cytotoxicity;
they may constitute two syndromes of the same spectrum.
2.4.1.3. Cytokines and chemokines. The levels of most of the major proin-
ﬂammatory cytokines have been found elevated during AOSD but the
cytokine proﬁle is not speciﬁc and cannot differentiate AOSD patients
from subjects with sepsis. The cytokine proﬁle has thus a limited use
in clinical practice [53].
The proinﬂammatory IL-1β, whose activation results mainly from
caspase-1 cleavage through the inﬂammasome activation, has been im-
plicated in the pathogenesis of AOSD [54]. Its serum concentration was
signiﬁcantly higher in patients than in controls. The most striking argu-
ment for its involvementwas given by Pascual et al. in the context of the
juvenile form of the disease [55]. This team has shown that peripheral
blood mononuclear cells of healthy subjects incubated with serum
from patients with Still's disease secrete large amounts of IL-1β andgen-associated or damage-associated molecular patterns) set ﬁre to a dysregulated NLRP3
ines (i.e., interleukin (IL)-1β and IL-18) and then Th1-polarization of CD4-lymphocytes. At
e and neutrophil recruitment. IL-1β – upstream of TNFα, IL-8, and IL-6 – induces its own
s and fast release of ferritin. IL-18 triggers a natural killer (NK) cell-mediated IFNγ produc-
totoxic function is decreased. In some cases, macrophage activation can lead to reactive
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emerged from reports that showed the dramatic efﬁcacy of anti-IL-1
treatments in AOSD (see Section 5 below). The absence of association
between polymorphisms in the genes of IL-1β or those of its receptor
antagonist and AOSD susceptibility [56], suggests an interplay
between pathogens and a genetically determined dysregulation of
IL-1β processing.
Interleukin-18, another proinﬂammatory cytokine processed
through the inﬂammasome machinery, induces the production of Th1
cytokines [57,58]. Compared with healthy controls, its level was higher
in AOSD patients' sera [17,31], synovial biopsies [59], lymph nodes [60]
and the liver where locally activated macrophages produce a high
amount of IL-18 and may contribute to AOSD-related hepatitis [61].
IL-18 levels were also signiﬁcantly higher in patients with AOSD-
related RHL [62]. These mechanisms may reinforce the pathological
secretion of IFNγ by NK cells under the effect of IL-18. Finally, IL-18
should be useful to monitor the response to treatment [59,63–65] but
it remains unclear whether IL-18 could serve or not as a therapeutic
target [66].
In untreated AOSD, the levels of IL-6 were found increased both in
salmon-colored skin rash specimens and in serum and correlated
with disease activity [31,32,67]. This cytokine may also be responsible
for some clinical features of AOSD (fever, skin rash) and for the produc-
tion of acute-phase proteins by the liver. Strong evidence for the IL-6
pivotal role in the development of SOJIA has been previously reviewed
[68]. However, IL-6 and its receptor (IL-6R) are downstream of IL-1β,
and IL-6 increased levels may be consecutive to overproduction of
IL-1β.
Tumor necrosis factor (TNF)-α levels were also found increased in
sera and tissues from AOSD patients but not correlated with disease
activity [17,35]. Conversely, its type 2 soluble receptor level correlated
with serumC reactive protein (CRP) andhas beenproposed as an activity
marker [17].
Moreover, many chemokines are involved in the inﬂammatory reac-
tion. In AOSD, two of them are of particular interest. The above-
mentioned CXCL8 is a major neutrophil inducer. The fractalkine
(CX3CL1) was correlated with the disease activity and with the levels of
serum CRP, ferritin, IL-18, and soluble IL-2 receptor (CD25). It was also
correlated with the onset of RHL [69].
2.4.1.4. Innate immune system receptors. Toll-like receptor (TLR) 7 liga-
tion promotes the recruitment of neutrophils and the ampliﬁcation of
Th17-driven inﬂammatory responses. A recent study demonstrated
that theTLR7-MyD88 pathway was overexpressed in the dendritic
cells of AOSD patients vs. healthy controls. The expression levels of
TLR7 were positively correlated with AOSD activity and with the
serum levels of cytokines IL- 1β, IL-6, IL-18, and IFN-γ. After treatment,
remission was associated with decreased TLR7 levels. Nevertheless, the
receptor expression proﬁle was similar to that of patients with systemic
lupus erythematosus and may reﬂect only the involvement of the TLR7
pathway during inﬂammatory diseases [70].
Inﬂammasomes are multiprotein complexes whose activation
depends on the recognition of various stimuli such as PAMPs
(pathogen-associatedmolecular patterns) or DAMPs (damage-associated
molecular patterns) [71]. These complexes are responsible for pro-IL-1β
and pro-IL-18 activation. Recent publications have suggested that
an abnormality of the NLRP3 (Nod-like receptor 3 or cryopyrin)
inﬂammasome could be an important mechanism in AOSD patho-
physiology [72,73]. So far, no polymorphism in the NLRP3 gene has
been identiﬁed in AOSD patients. Thus, the inﬂammatory status of
AOSD could result either from a reduced threshold of activation or
from a deregulation of the inﬂammasome. Antoniou et al. have re-
cently provided evidence for an increased NLRP3-mediated IL-1β
production in one case of atypical AOSD [72]. This response was
markedly decreased after remission, which is similar to the pattern
of response to treatment seen in patients with autoinﬂammatorydiseases due to NLRP3 mutations: the cryopyrin-associated periodic
syndromes (CAPS) [74].2.4.2. Adaptative immunity
2.4.2.1. Th1 cellular immune response. The increased concentrations of
the α-soluble receptor of IL-2 (CD25) seen in AOSD patients argue for
T cell activation and proliferation [17,31]. Compared with healthy
controls, IL-4-producing T cells in serum, skin, and synovium in AOSD
patients predominate over IFN-γ-producing T cells. This reﬂects a Th1
polarization of CD4+ T cells, which then activate macrophages, NK
cells, and promote cell-mediated immunity [75].2.4.2.2. Th17 and Treg involvement. The differentiation of naïve T cells
into Th17 cells is supported by several cytokines including IL-1β, IL-6,
and IL-23. Furthermore, IL-18 synergizes with IL-23 to promote IL-17
production by IL-23-primed CD4+ T cells. Interleukin-17 is a proin-
ﬂammatory cytokine that ampliﬁes inﬂammation, stimulates the pro-
duction of neutrophil-recruiting chemokines (including CXCL-8), and
enhances granulopoiesis [76]. Recently, Chen et al. have shown that
circulating Th17 cells are signiﬁcantly higher in patients with active un-
treated AOSD than in healthy controls [77]. The levels of Th17 correlated
with the disease activity, with ferritin levels, and with remission after
treatment. However, it is still unknown whether Th17 cells are part of
the pathogenic mechanism or only markers of AOSD progression.
Indeed, Th17 polarization could occur downstream of other more com-
plex mechanisms. For example, somemissense mutations of the NLRP3
gene may cause inﬂammasome hyperactivation, overproduction ofIL-
1β, and a subsequent increase in Th17 differentiation [78]. Nevertheless,
some data propose Th17 cells as possible targets for therapy [78,79].
Finally but not surprisingly, it has been shown that circulating CD4+
CD25high regulatory T cells (Treg) and transforming growth factor
(TGF)-β are inversely correlated with AOSD activity scores. Higher
levels of Tregwould correlatewith a better prognosis of the disease [80].2.4.3. Is AOSD an autoinﬂammatory disease?
Autoinﬂammatory diseases affect primarily the innate immune sys-
tem and are characterized by an inappropriate activation of the phago-
cytes. Historically, this group comprised rare disorders of Mendelian
inheritance like CAPS, TNF receptor-associated periodic syndromes
(TRAPS), and familial Mediterranean fever. These share with AOSD the
absence of evidence for a link with microorganisms and the absence of
autoantibodies or autoantigen-speciﬁc T cells. Their typical clinical
manifestations resemble closely those of AOSD and include recurrent
inﬂammatory attacks of fever with skin involvement, serositis, and ar-
thritis. As in AOSD, a dramatic response to IL-1β blockade is characteris-
tic of these autoinﬂammatory disorders. Nevertheless, some features
seem to differentiate AOSD: the characteristic proﬁle of the fever, the
longer duration of the exacerbations, and the possible occurrence of
bone and cartilage destruction. Although RHL has been recently catego-
rized as an autoinﬂammatory disease, it is less likely to occur in the con-
text of autoinﬂammatory diseases than in AOSD. Furthermore, most of
the autoinﬂammatory diseases are hereditary and due to mutations in
a single gene whereas AOSD does not cluster in families, ethnic groups,
or geographic areas. Thus, AOSD has been categorized as a multigenic
(or complex) autoinﬂammatory disorder and put it at the crossroads
of autoinﬂammatory and autoimmune diseases [54,81–83].3. Clinical features, diagnostic tests, and diagnostic criteria
Most of the herein discussed features come from the analysis of the
main case series published in themedical literature and summarized in
Table 1 [5,11–13,84–89].
Table 1
Comparison between the main literature series dedicated to adult-onset Still's disease.
Pouchot [13] Fautrel [84] Pay [85] Cagatay [11] Zhu [86] Kong [87] Colina [89] Chen [12] Gerfaud-Valentin [4]
Findings 1991 2002 2005 2007 2009 2010 2011 2012 2013
Number of patients 62 72 95 84 77 104 76 61 57
Males 34 (55) 45 (47) 25 (30) 23 (30) 32 (42) 29 (48) 27 (47)
Females 28 (45) 50 (53) 59 (70) 54 (70) 44 (68) 32 (52) 30 (53)
Diagnosis at ages 16 to 35 50 (81) 45 (54) 51 (66) 43 (70) 27 (47)
Age at diagnosis (years)
Mean 35.2 32.5 [16–64] 36 [11–70]
Median [range] 27 [16–82] 36 [16–75]
Delay to ﬁnal diagnosis (months)
Mean 21 months
Median [range] 3 [0.5–84] 4 [0–312]
Fever 62 (100) 61 (85) 94 (99) 80 (95) 77 (100) 104 (100) 76 (100) 61 (100) 54 (95)
Weight loss 17 (18) 16 (19) 25 (44)
Rash 54 (87) 51 (71) 78 (82) 50 (60) 66 (86) 98 (94) 44 (58) 48 (79) 44 (77)
Arthralgia/arthritis 62 (100) 64 (89) 95/95 (100) 81 (96) 67 (87) 93 (90) 55 (72) 49 (80) 54 (95)
Sore throat/pharyngitis 57 (92) 38 (53) 63 (66) 55 (66) 60 (78) 81 (78) 28 (37) 51 (84) 30 (53)
Myalgia 52 (84) 66 (70) 11 (13) 43 (56) 8 (13) 22 (36) 25 (44)
Lymphadenopathy 46 (74) 32 (45) 35 (37) 28 (33) 35 (45) 69 (66) 29 (38) 32 (52) 34 (60)
Splenomegaly 34 (55) 40 (42) 24 (29) 22 (29) HSMG 46 (44) 22 (29) 39 (64) 17 (30)
Hepatomegaly 27 (44) 43 (45) 32 (38) 9 (12) 13 (21) 12 (21)
Pleurisy 33 (53) 21 (22) 8 (10) 9 (12) Both 31 (30) 18 (24) 7 (11) 10 (18)
Pericarditis 23 (37) 15 (21) 8 (8) 10 (12) 2 (3) 15 (20) 6 (10) 11 (19)
Abdominal pain 30 (48) 1 (1) 16 (21) 2 (3) 10 (18)
Evolutive onset
Monocyclic 20 (21) 28 (33) 20 (26) 17 (30)
Polycyclic 16 (17) 28 (33) 23 (30) 25 (44)
Chronic 39 (41) 23 (27) 33 (43) 15 (26)
White blood cells ≥104/mm3 58 (94) 64 (89) 69 (82) 63 (82) 102 (98) 69 (91) 49 (80) 39/54 (72)
PMN ≥80% 55 (89) 50 (69) 60 (79) 35 (56) 36 (59) 39/50 (78)
Anemia 42 (68) 30 (36) 29 (38) 72 (69) 40 (53) 11 (18) 32/49 (65)
Heightened C-reactive protein 87 (97) 52 (66) 86 (92) 74 (97) 52/52 (100) 49/51 (96)
Elevated eythrocyte sedimentation rate 62 (100) 89 (94) 79 (94) 44 (90) 100 (96) 73 (96) 60 (98) 24/25 (96)
High serum ferritin (N500 μg/L) 50 (69) 81 (89) 80 (95) 30 (97) 75 (72) 68 (89) 17/18 (94) 39/51 (76)
Glycosylated ferritin ≤20% 52 (72) 28/37 (76)
Elevated liver enzymes 47 (76) 53 (74) 59 (64) 30 (36) 48 (62) 65 (62) 57 (75) 43 (70) 27/50 (54)
Negative for rheumatoid factor 58 (94) 71 (99) 63 (94) 99 (95) 72 (95) 57 (93) 49/49 (100)
Negative for antinuclear antibodies 55 (89) 66 (92) 69 (93) 104(100) 69 (91) 55 (90) 4/52 (8)
Values expressed as number (percentage), median [range], or positive/tested (percentage of tested) — HSMG: hepatosplenomegaly.
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The following constellation of non-speciﬁc symptoms could be
evocative of AOSD.
Fever occurs in 60 to 100% of the patients. It typically spikes daily
or twice daily, the highest temperatures (N39 °C) occurring in the
evening. Fever precedes usually the onset of other manifestations.
Nowadays, in Europe, AOSD accounts for 3 to 20% of fevers of
unknown origin [90,91].
Joint pain is the most common symptom (70 to 100%). Arthralgia
and arthritis involve predominantly the wrists, the knees, and the
ankles. Even though arthritis is initiallymild and transient, itmay evolve
into a chronic destructive symmetrical polyarthritis with a classical
carpal ankylosis [3,92]. Joint ﬂuid aspiration often reveals an inﬂamma-
tory ﬂuid with neutrophil predominance [13].
In 60 to 80% of AOSD cases, a macular or maculopapular evanescent
salmon-pink skin rash appears together with the fever spikes. It is
predominantly found on the proximal limbs and trunk [90,93].
Sore throat can be an early symptom of AOSD. It occurs in about
70% of the patients before or during the ﬁrst month of each disease
ﬂare. It has been linked to a viral infection, an inﬂammation of the
crico-arytenoid joints, or an aseptic non-exudative pharyngitis
[94].
Other symptoms were reported during AOSD: myalgia (45%),
enlargement of the lymph nodes (50%), splenomegaly (40%), hepato-
megaly (30%), pleurisy (21%), pericarditis (16%), weight loss (27%),
and abdominal pain (18%). Interstitial lung inﬁltrates have been reported
but improved rapidly after treatment [95–98]. Pulmonary hypertension
is rare [99,100].Much less frequent manifestations may be found in the litera-
ture, mainly in single-case reports. These include ischemic stroke,
reversible posterior leukoencephalopathy syndrome [101], bilater-
al perception of deafness [102], aseptic meningitis or encephalitis
[103–107], collapsing glomerulopathy [108,109], membranous
glomerulonephritis [110], even necrotizing crescentic glomerulo-
nephritis [111,112] or tubulo-interstitial nephritis [113], conjunc-
tivitis (local case), uveitis [114], retinopathy [115], inﬂammatory
orbital pseudotumor [116], pseudo-angiocholitis [117]; portal
vein thrombosis [118], necrotizing granulomatous lymphadenopa-
thy [119], and angioedema [120].
3.2. Laboratory ﬁndings
Laboratory tests reﬂect the non-speciﬁc systemic inﬂammatory
nature of the disease.
Increases in the erythrocyte sedimentation rate and CRP level are
common in AOSD (90 to 100%). A neutrophilic leukocytosis (N80% poly-
morphonuclear cells) is found in about 80% of cases and allowed differ-
entiating AOSD from other fevers of ‘unknown origin’ [88]. As in other
inﬂammatory diseases, anemia (50%) and thrombocytosis (26%) are
common ﬁndings.
Recently, some authors suggested that uncommon conditions such
as AOSD, RHL, catastrophic anti-phospholipid syndrome and septic
shock should be included under a common syndrome entity termed
‘hyperferritinemic syndrome’ to underline the pro-inﬂammatory role
of ferritin. They have suggested that exceptionally high serum ferritin
levels observed in these four clinical conditions may contribute to the
development of a cytokine storm [44]. During AOSD, serum ferritin
Table 2
Differential diagnosis of adult-onset Still's disease.
Diseases Diagnostic tests
Infections
Viral infections Serology, PCR
HIV
Herpesviridae
Measles, rubella…
Viral hepatitis
Parvovirus B19
Infective endocarditis Blood cultures, ultrasonography
Borreliosis, Brucellosis, Yersiniosis Serology, PCR
Mycoplasma pneumoniae, syphilis… Serology, PCR
Toxoplasmosis Serology, PCR
Neoplasia
Malignant lymphoma CT, PET/CT, Bone marrow
examination, lymph node biopsy
Multicentric Castleman disease Lymph node biopsy
Angioimmunoblastic T cell lymphoma Lymph node biopsy
Drug reactions
Drug reaction with eosinophilia
and systemic symptoms
Eosinophil count, skin biopsy
Autoimmune diseases
Systemic lupus erythematosus Antinuclear autoantibodies
Idiopathic inﬂammatory myositis Idem, muscle biopsy
Rheumatoid arthritis Anti-citrullinated peptids
autoantibodies, rheumatoid factor
Systemic vasculitides ANCA, tissue biopsy, arteriography
Autoinﬂammatory diseases
Familial Mediterranean fever Familial history, MEFV gene analysis
Mevalonate kinase deﬁciency Urinary mevalonic acid, mevalonate
kinase analysis
TNF receptor-associated periodic
syndrome
TNFRSF1A gene analysis
Reactive arthritis HLA B27, magnetic resonance imaging
Other
Sarcoïdosis
Neutrophilic dermatosis
Kikuchi–Fujimoto disease
PCR: polymerase chain reaction — CT: computed tomography — ANCA: anti-neutrophil
cytoplasmic antibodies.
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fectious, or neoplastic diseases. A threshold of ﬁve times the normal
value (i.e., 1000 μg/L) is suggestive of AOSD [121,122]. However, the
speciﬁcity for AOSD remains poor (41 to 46%) since similar levels may
be found during infection, neoplastic conditions, or storage diseases
such as Gaucher's disease [39,122,123]. So, serum ferritin is of limited
value in diagnosing AOSD but may be useful as a marker of disease
activity [124,125].
In the early 2000s, Fautrel et al. underlined the usefulness of low
glycosylated ferritin (GF) as a diagnostic marker for AOSD. In a retro-
spective study of 49 AOSD cases and 120 controls, GF was signiﬁcantly
lower in cases (15.9 ± 11.9%) than in controls (31.5 ± 18.7%). Further-
more, combining a GF level b20% with a ﬁvefold elevation of serum
ferritin led to a 92.9% speciﬁcity for AOSD (43.2% sensitivity) [39]. How-
ever, this conditionmay be also encountered in RHL of other cause than
AOSD [126]. From a study on 14 patients, Vignes et al. concluded that a
persistent low GF level could be a useful diagnostic marker for AOSD
several months after disease remission [127]. This could not be con-
ﬁrmed by another study because only one out of the ﬁve GF levels
assayed during remission within the ﬁrst 3 years of follow-up was
b20% [4].
Liver abnormalities are common (65%); mainly a mild to moderate
increase in aminotransferase activity.
Pathology examinations can help in differentiating AOSD from lym-
phoma or other inﬂammatory diseases in the initial diagnostic ap-
proach. A non-speciﬁc interstitial inﬂammation is the most common
ﬁnding in the myocardium, lung, liver, and gastrointestinal tract tissues
[128]. Hepatic necrosis has been described in fulminant-hepatitis-
complicated AOSD [129,130]. Bonemarrow examination rules out lym-
phoma or conﬁrms hemophagocytosis [4,40]. However, a non-speciﬁc
‘reactive inﬂammatory bone marrow’ including granulocytic hyperpla-
sia and hypercellularity seems to be the most prevalent abnormality
on bone marrow examination [85]. Studying lymph node biopsies
in 12 AOSD patients, Jeon et al. proposed a four-pattern classiﬁcation
of histological abnormalities in which the main subset included
paracortical hyperplasia, vascular proliferation, scattered large B/T
immunoblasts, and a reactive lymphocyte inﬁltrate [131]. Data on unse-
lected patients are lacking to conﬁrm this classiﬁcation.
Radiographs are not usually very helpful in establishing the diagno-
sis; they are either normal or show soft-tissue swelling, joint effusion, or
mild periarticular demineralization. In one study, 41%of the patients de-
veloped a distinctive pattern of intercarpal and carpometacarpal joint
space narrowing (bilateral in 69%) that led to pericapitate ankylosis in
25% of the cases [13]. Patients who have the chronic articular disease
pattern present more often with joint erosions [4]. Computed tomogra-
phy can complete the clinical picture showing deep lymph nodes,
splenomegaly, hepatomegaly, or serous effusions but it is often per-
formed to rule out an underlying neoplastic disease [132,133].
Literature data on 18FDG-PET–CT in AOSD are limited to a few clini-
cal cases [134]. A previous report on nine18FDG-PET–CTshas shown that
the lymph nodes and the glands are the main sites of hypermetabolism
[4]. In the case of fever of unknown origin, 18FDG-PET–CT may support
the diagnosis of AOSD by rejecting the hypotheses of infection, solid
tumor, or large vessel vasculitis [135,136]. The technique may be inter-
esting inmonitoringdisease progression and the response to treatment;
this has to be conﬁrmed in other prospective cohorts [134,137].
So, as no clinical or laboratory test is speciﬁc, the diagnostic of AOSD
remains one of exclusion. Infectious, neoplastic and autoimmune
diseases can mimic the clinical manifestation of AOSD and should be
ruled out before considering this diagnosis (Table 2).
3.3. Diagnostic criteria
Several sets of classiﬁcation criteria have been proposed for research
and diagnosis; all stemmed from retrospective studies [84,123,
138–140]. In a recent study comparing four sets of diagnostic criteriain a Chinese population, the Yamaguchi set had the highest sensitivity
(78.57%) and a 87.14% better accuracy [141]. This study did not include
Fautrel's criteria described in 2002 that included GF ≤20% and allowed
avoiding the exclusion criteria required in the Yamaguchi set. Fautrel's
classiﬁcation was 80.6% sensitive and 98.5% speciﬁc [84]. Now, most
studies on AOSD include patients who meet Yamaguchi's (Table 3)
and/or Fautrel's (Table 4) criteria.
4. Outcome, prognosis, and complications of AOSD
4.1. Natural history of AOSD
Conventionally, three patterns of natural history of AOSD have been
described on the basis of the course of the disease [13,138,142]. Mono-
cyclic AOSD is characterized by a systemic self-limited single episode
that fades within months (median: 9 months); most patients become
asymptomatic within a year [142]. The polycyclic (or intermittent) pat-
tern of AOSD associatesmultiple ﬂareswith systemic or joint symptoms
separated by remissions lasting a couple of weeks to a couple of years;
ﬂares would become less severe over time. Finally, chronic AOSD is
a persistently active disease usually associated with polyarthritis. In
the latter pattern, disability can be important. The distribution of the
patterns in the patients varies widely. For example, the chronic onset
represented 43% of AOSD cases in some rheumatologic series [5]where-
as it represented only 26% in a recent internal medicine series [4]. On
Table 3
Yamaguchi classiﬁcation criteria for adult-onset Still's disease [123].
Major criteria Minor criteria Exclusion criteria
Fever ≥39 °C
lasting 1 week or longer
Sore throat Infections
Arthralgia or arthritis
lasting 2 weeks or longer
Recent development of signiﬁcant lymphadenopathy Malignancies (mainly malignant lymphoma)
Typical rash Hepatomegaly or splenomegaly Other rheumatic disease (mainly systemic
vasculitides)
Leucocytosis ≥10,000/mm3 with ≥80% polymorphonuclear cells Abnormal liver function tests
Negative tests for antinuclear antibody (IF) and rheumatoid
factor (IgM)
Five or more criteria required, of whom 2 or more must be major.
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cyclic AOSD, and 40% a chronic AOSD (Table 1).
Recent data have suggested that these three patterns may be
grouped into only two: a systemic form that includes the monocyclic
and the polycyclic patterns and another chronic articular form. In fact,
it is probable that the immunological imbalance would be different
between the two forms,whichwould explain the difference in effective-
ness of speciﬁc biologic agents (see Section 5.)[143,144].
4.2. Prognosis
Few studies have focused on the prognostic factors in AOSD. It seems
that polyarthritis and joint erosion at disease onset are predictive of a
chronic progression and a poor functional prognosis [4,5,138].
Conversely, high fever (N39.5 °C) at disease onset correlated with a
systemic form, mainly monocyclic AOSD [4]. Lymphadenopathy and
splenomegaly were more frequent in RHL-complicated AOSD [40].
Splenomegaly has been also associated with steroid dependence [145].
Kong et al. have found that leukocytosis≥30,000/mm3was associat-
edwith AOSD relapses [87]. An elevated erythrocyte sedimentation rate
or CRP has been found signiﬁcantly associated with poor prognoses or
higher relapse rates [87,145]. Thrombocytopenia at disease onset
could predict the occurrence of complications [4] and has been associat-
ed with high mortality rates during RHL-complicated adult systemic
diseases including AOSD [146]. Asmentioned above, high serum ferritin
levels correlatedwith disease activity and have been linked to a chronic
pattern, recurrent ﬂares, and poor prognoses [5,87,124,125]. GF assess-
ment seems to reduce the time to diagnosis and thereby favor a good-
prognosis monocyclic course of AOSD [4]. Of note, the highest serum
ferritin levels as the lowest GF levels would correlate with the occur-
rence of RHL in AOSD patients [4,40,44].
In summary, in AOSD, it is difﬁcult to deﬁne strongprognostic factors
on the basis of retrospective studies that identiﬁed heterogeneous prog-
nostic criteria. According to our experience and knowledge, we suggest
distinguishing two AOSD phenotypes according to the clinical presenta-
tion of the disease at diagnosis. On the one hand, a highly symptomatic
onset with high fever, serositis, elevated liver enzymes, arthralgia but
rare arthritis, which would evolve into a systemic (monocyclic or
polycyclic) AOSD; and, on the other hand, a more indolent onset
with arthritis, sometimes radiological joint erosions, and poor systemic
symptomatology, which would have a chronic course. Further studies,Table 4
Fautrel classiﬁcation criteria for adult-onset Still's disease [84].
Major criteria Minor criteria
Spiking fever ≥39 °C Maculopapular rash
Arthralgia Leukocytosis ≥10,000/mm3
Transient erythema
Pharyngitis
Polymorphonuclear cells ≥80%
Glycosylated ferritin≤20%
Four or more major criteria required or 3 major + 2 minor criteria.ideally prospective, in independent populations are needed to support
this suggestion.4.3. Complications
The disease may present several rare manifestations which can
limit life expectancy. RHL, which occurs in about 12 to 15% of
AOSD cases (probably less in rheumatologic cohorts), is the most
frequent [4,40,147]. The prognosis of RHL-complicated AOSD
seems better than that RHL in other settings; only one patient died
among the total of 14 cases reported on by Hot et al. and Arlet
et al. [38,146]. Other complications are even rarer; these include:
myocarditis [148–163], tamponnade and constrictive pericarditis
[164,165], endocarditis [166]; shock, multiple organ failure, acute
respiratory distress syndrome, intra-alveolar hemorrhage, dissemi-
nated intravascular coagulation [167–181]; thrombotic microangi-
opathy [182–184]; and fulminant hepatitis [129,130]. As in other
autoinﬂammatory syndromes, AA amyloidosis has been reported
in a few cases of chronic uncontrolled inﬂammation [185–189].
Put together, these complications of systemic AOSD concerned
about one third of AOSD patients seen in a tertiary center of internal
medicine [4].
The current treatments of AOSD are also source of many compli-
cations. In a cohort of 57 subjects, 21% of NSAIDs-treated patients
experienced gastrointestinal side effects despite proton pump
inhibitor administration, 75% of corticosteroid-treated patients
suffered from adverse events (Cushing syndrome, osteoporosis,
aseptic osteonecrosis, diabetes, hypertension, cataract, psychiatric
disorders) whereas one third of methotrexate-treated patients
experienced complications (elevated liver enzymes (15%), low
blood cell counts (10%), and cough (6%)) [4]. Furthermore, the
treatments used in AOSD would increase the risk of infectious
complications [124,145].
Nevertheless, in Western countries, AOSD remains a benign and
non-fatal disease with a low mortality rate [189]; only two deaths
(3%) could be attributed to the disease in a report by Pouchot et al.
[13] and none of the three deaths in a report by Gerfaud-Valentin
et al. [4]. In contrast, two recent studies in Asiatic patients [124,
145] have reported high mortality rates (9.26% and 10%, respective-
ly) due to infections and disease progression but only a small
proportion of the patients had received biologic agents. Despite
differences in access to health care between countries, multicentric
studies are needed to investigate whether AOSD prognosis is
signiﬁcantly inﬂuenced by ethnicity. In the literature, deaths during
AOSD were due to infections [23,124,138,190], acute respiratory
distress syndrome [124,191], multiple organ failure during RHL
[148,192], thrombotic microangiopathy [193,194], or involvement
of the central nervous system [192,193,195].
Overall, current studies suggest that AOSD is a relatively benign dis-
ease and that most deaths are related to side effects of long-term
treatments.
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As the current information on treatment efﬁcacy is obtained from
small retrospective case series and not from prospective double-
blinded randomized trials, the treatment of AOSD remains empirical.
Recently, themanagement of AOSDbeneﬁted fromproofs of the efﬁcacy
of targeted biotherapies.
5.1. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
In two retrospective studies, NSAIDs failed to control the symptoms
of AOSD in 82% to 84% of patients whereas 20% experienced adverse
events [4,196]. The risk/beneﬁt ratio being unfavorable, NSAIDs should
no longer be considered as a ﬁrst line treatment in AOSD but rather a
supportive treatment during the diagnostic process and be reserved
for the early reminiscences of the disease whenever corticosteroids
and disease-modifying antirheumatic drugs (DMARDs) prove insufﬁ-
cient [196]. Here, high-dose indomethacin (150–250 mg/day) should
be used ﬁrst [13,138,142].
5.2. Corticosteroids
Corticosteroids are effective in controlling the disease in about 65%
of patients [66,85]. Their efﬁcacy is greater in the systemic pattern of
AOSD [196]. Based on retrospective case series, the initial dosage ranged
from 0.5 to 1 mg/kg/day. Patients with serious visceral involvement
could achieve a quick response with intravenous infusion of high-dose
methylprednisolone. The response to corticosteroids is often quick: it
occurs within a couple of hours or a few days [40,154,156,158,163].
The tapering begins usually after 4 to 6 weeks. Kong et al. have reported
that patients treatedwith high prednisone dosage (≥40mg, 0.8 mg/kg)
achieved quicker remissions and had less relapses than those who re-
ceived a lower dosage [88], which is consistent with the recent ﬁndings
of Kim et al. [89]. Furthermore, incomplete-responder patients to a daily
single dose of prednisone could achieve remission with multiple daily
doses of prednisone or dexamethasone [13,197]. Unfortunately, steroid
dependence occurs in 42% to 45% of the cases. This exposes the patients
to serious mid- and long-term side effects (see Section 4.3.) [4,145].
Steroid-dependence has been associated with splenomegaly, low rate
of GF, elevated erythrocyte sedimentation rate, or young age at AOSD
onset [4,146]. These ﬁndings argue for an early addition of a steroid-
sparing treatment in such patients.
5.3. Methotrexate and other disease-modifying anti-rheumatic
drugs (DMARDs)
While few data argue for a beneﬁcial use of hydroxychloroquine in
AOSD [13,85], methotrexate remains the most used DMARD in this
disease [4], especially for its steroid-sparing effect. In 1999, Fautrel
et al. reported on low-dose methotrexate (7.5–17.5 mg/week) in 26
steroid-dependent patients. Twenty-three (88%) patients achieved a
partial remission and 18 (69%) a complete remission. Eleven patients
(39%) stopped corticosteroids whereas the mean daily prednisone
intake was decreased by 21.5 mg (i.e., 69%) [198]. The effect of metho-
trexate is the same in systemic and in chronic articular AOSD [196,198];
it allows controlling the disease in 40% to 70% of steroid-dependent
AOSD patients [4,196]. Thus, methotrexate should be added to predni-
sone when the latter fails to control the disease or in case of steroid-
dependence. The presence of liver enzyme abnormalities does not con-
traindicatemethotrexate prescription, but a close biological monitoring
is necessary.
A few retrospective data on cyclosporineA suggest that it could be as
effective as methotrexate in systemic AOSD [196,199]. Nonetheless, its
lower tolerance argues for its use in the case of severe complications
with failure of intravenous corticosteroids [199].5.4. Intravenous immunoglobulins (IVIG)
According to a few retrospective case series, 4% to 43% of AOSD pa-
tients receive IVIG during the disease course [145,196]. In a previous
study [4], IVIG were signiﬁcantly more prescribed in non-monocyclic,
complicated and steroid-dependent AOSD although no data are avail-
able to support this choice. Indeed, robust data on IVIG in AOSD are
still poor. In two open-label studies, they were shown effective in 8/14
patients, early in the disease course [200,201]. For Kim et al., IVIG have
no consequence on the course and prognosis of AOSD [145]. Their
corticosteroid-sparing ability remains to be determined. However, it
may be worth to use IVIG in life-threateningmanifestations as reported
in RHL [202]. Importantly, IVIG are well tolerated; only one patient
among 23 IVIG-treated patients presented a severe adverse event
(an acute renal failure) [4]. Finally, it should be noted that monthly in-
fusions of IVIG are useful to control AOSD during pregnancy [14,203].
5.5. Biologic agents
A growing body of evidence supports the efﬁcacy of several biologic
agents in the treatment of corticosteroid- and DMARD-refractory AOSD.
In recent case series, about one quarter of the cohorts were adminis-
tered these biotherapies [4,196]. Details on the major studies discussed
in this section are shown in Table 5.
5.5.1. TNFα-blockers
The ﬁrst open-label prospective trial of etanercept, a recombinant
form of the human 75-kd TNF receptor fusion protein, in 12 refractory
chronic polyarthritis was published in 2002 [204]. At 6 months, seven
patients achieved at least ACR-20 response criteria [205]. Among the
three patients with concomitant systemic symptoms of AOSD, only
one improved. Between 2001 and 2004, three small studies on a total
of 13 patients with severe chronic AOSD reported impressive results
with inﬂiximab (3–5 mg/kg at weeks 0, 2, 6 and then once every 6–
8 weeks), a chimeric monoclonal antibody that binds to soluble TNFα
and inhibits the interaction with its cellular receptors. Inﬂiximab had a
marked and rapid efﬁcacy on both systemic and articular symptoms
and also a steroid-sparing effect [206–208]. However, these enthusiastic
results should be tempered by the results of the French ‘Club
Rhumatisme et Inﬂammation’ study on inﬂiximab and etanercept in
20 chronic AOSD cases [209]. After a mean follow-up of 13 months,
ﬁve patients had complete remissions (one with etanercept and four
with inﬂiximab), 11 achieved partial remissions, and TNFα-blockers
failed to control the disease in the remaining four patients. At the last
visit, 11 patients had discontinued anti-TNFα therapy because of insuf-
ﬁcient efﬁcacy and four because of side effects. Data on adalimumab are
limited to a few cases [210]. It should be noted that RHL has been asso-
ciated with etanercept [211] and adalimumab [212] in two patients.
In summary, TNFα-blockers may be interesting in chronic
polyarticular refractory AOSD probably more than in the systemic pat-
terns of the disease [4,85,145,196]. Although a head-to-head comparison
is not available, inﬂiximab may be more effective than etanercept; it in-
duced more remissions. Unfortunately, the efﬁcacy of TNFα-blockers
seems to be limited in time and switching from one to another is useful
in about 50% of cases [4,213].
5.5.2. IL-1β antagonists
Anakinra is a recombinant receptor antagonist of IL-1 used in
cryopyrin-associated periodic syndromes and other autoinﬂammatory
diseases [214,215]. Its efﬁcacy in AOSD (100 mg daily subcutaneous
injection) supported the pivotal role of IL-1β in the pathogenesis of
the disease [55].
Rudinskaya and Trock in 2003, then Vasques Gondhino et al. and
Fitzgerald et al. in 2005 [216–218] reported on the ﬁrst six refractory
AOSD cases efﬁciently treated with anakinra. In 2007, two other
series totalizing eight patients described a good efﬁcacy of anakinra in
Table 5
Main case series on biologic agents in refractory adult-onset Still's disease.
Targeted biotherapy and
1st author, year [Ref.]
Patients AOSD pattern Design Mean follow-up
(months)
Complete
remissions (n; %)
Partial
remissions
Steroid-spared
(n; MSDD (mg))
Steroid
stopped
Infections
(severe ones)
Severe
skin
rashes
Etanercept
Husni, 2002 [204] 12 CPA Prospective
open-label
6 0 7 NA 0 1 (0) 0
Inﬂiximab
Cavagna, 2001[206] 3 CPA Case series 2 0 2 NA NA 0 (0) 1
Kraetsh, 2001 [207] 6 S; CPA Case series NA 4; 67 2 3 NA 0 (0) 0
Kokkinos, 2004 [208] 4 S; CPA Case series 11 4; 100 0 2 1 0 (0) 0
Etanercept, inﬂiximab
Fautrel, 2005 [209] 20 CPA Case series 13 5; 25 11 NA NA 2 (0) 0
Anakinra
Fitzgerald, 2005 [218] 4 S Case series 11.5 3; 75 1 4 3 1 (0) 0
Kalliolias, 2007 [219] 4 S Case series 11 1; 25 3 4 3 0 (0) 0
Kötter, 2007 [220] 4 S; CPA Case series 21 4; 100 0 ≥2 NA 0 (0) 0
Lequerré, 2008 [221] 15 S; CPA Case series 14 9; 64 2 8; MSDD: 18.2 2 2 (0) 1
Laskari, 2011 [222] 25 S; CPA Case series 15 21; 84 3 NA 12 7 (0) 3
Nordström, 2012 [226] 12 S; CPA Prospective
randomized
open-label
6 6; 50 NA NA; MSDD: 10.8 3 0 (0) 0
Giampietro,
2013 [223]
28 S (54%); CPA
(46%)
Case series 23 12; 43 4 15; MSDD: 24.7 NA NA (0) 2
Tocilizumab
Puéchal, 2011 [240] 14 CPA Case series 6 8; 57 1 NA; MSDD: 13 NA 0 (0) 1
Cipriani, 2013 [241] 11 S; CPA Case series 12 9; 82 2 3 8 1 (0) 0
Elkayam, 2014 [242] 15 CPA Case series 16 12; 80 2 5; MSDD: 23.8 9 0 (0) 0
CPA: chronic polyarthritis— S: systemic pattern —MSDD: mean steroid dose decreasing — NA: not available.
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systemic symptoms [219,220]. The symptoms disappearedwithin a few
days after the ﬁrst injection and the inﬂammatory markers reverted to
normal within 2–4 weeks. Moreover, anakinra allowed a fast steroid ta-
pering. A self-limited injection-site erythema was the only adverse
event reported. However, relapses occurred within a few days of treat-
ment discontinuation.
The French ‘Club Rhumatisme et inﬂammation’ group provided the
two largest studies on anakinra in AOSD. In the ﬁrst, Lequerré et al.
reported on 15 anakinra-treated refractory AOSD patients of whom 13
had systemic symptoms [221]. In the second, Giampetro et al. reported
on a long-term follow-up of 28 patients. Initially, all responded positive-
ly to anakinra. After a 23-month mean follow-up, 16 patients were still
treated with anakinra of whom 12 achieved a complete remission. Four
patients among the six receiving anakinra without methotrexate
achieved a complete remission. In only three patients, anakinra discon-
tinuation was possible without relapse. Six additional patients experi-
enced tapering of anakinra: two achieved a sustained remission
whereas four relapsed. Less ﬂares occurred during a progressive dose
reduction from 7 to 3 injections/week than after the dose was immedi-
ately reduced to one injection every 2 days [222]. In these two studies,
the steroid-sparing effect of anakinra was important (see Table 5).
Several studies in SOJIA suggest a better efﬁcacy of anakinra when
administered early in the course of the disease [221,223,224]. Therefore,
the 2012 consensus treatment plans for new-onset SOJIA made
anakinra a second-line treatment to consider (just as methotrexate or
tocilizumab) when steroids alone fail to control the disease [224].
Moulis et al. have reported on two adult patients with dramatic side
effects secondary to conventional treatment that had a remarkable
response after administration of anakinra [225]. Laskari et al. reported
on 25 AOSD patients treated early (mean disease duration: 7 months)
with anakinra of whom 84% achieved a rapid (median: 0.2 months)
and sustained clinical remission after a 15-month median follow-up
period [222]. Moreover, comparing in a randomized manner the
outcomes of 12 AOSD patients treated with anakinra vs. 10 patients
treated with a DMARD in steroid-dependent AOSD, Nordström et al.reported greater improvements in the anakinra group [226]. According-
ly, whether a better efﬁcacy could be reached with an early treatment
with anakinra (avoiding the adverse effects of a prolonged
corticotherapy, and limiting the social impact of a poorly controlled dis-
ease) remains to be demonstrated [227].
Overall, anakinra seems to be rapidly and frequently efﬁcient, well
tolerated, and steroid-sparing in refractory AOSD. A persistent complete
remission could be achieved in 50 to 80% of cases versus 25% with
TNFα-blockers. However, the treatment is purely suspensive; relapses
could occur soon after discontinuation. As seen in SOJIA, the most im-
pressive results were obtained in the systemic forms of AOSD [221,
228,223]. Anakinra requires daily injections and is associatedwith com-
mon painful local adverse reactions. Thereby, and in the case of insufﬁ-
cient response to anakinra due to its short half-live, IL-1 antagonists that
have longer half-lives are promising. Canakinumab, a humanmonoclonal
antibody targeted against IL-1β, can be administered every 8 weeks and
rilonacept, a soluble dimeric trap fusion protein, can be administered
once a week. Both have been reported efﬁcient in AOSD and SOJIA
[229–232].5.5.3. IL-6 antagonists
As discussed above, IL-6 is markedly elevated in active AOSD and
was considered as a suitable target in the treatment of refractory
AOSD [32,35]. A few isolated reports have shown promising results
with tocilizumab, a humanized anti-IL-6 receptor antibody that
blocks membrane-bound and soluble IL-6 receptors in steroid-,
DMARD-, TNFα blocker- and even cyclosporine-refractory AOSD
[103,233–239].
In 2011, Puéchal et al. reported on the ﬁrst series of 14 patients with
refractory AOSD treated with 5–8 mg/kg tocilizumab every 2 or
4 weeks. Eleven patients completed successfully the 6-month study.
One patient withdrew because of necrotizing angiodermatitis, another
because of chest pain and chills at each infusion, and a third because
of systemic ﬂare. The mean Disease Activity Score (DAS) 28 dropped
from 5.61 to 2.91 at the 6-month follow-up visit. The systemic
717M. Gerfaud-Valentin et al. / Autoimmunity Reviews 13 (2014) 708–722symptoms resolved in six out of seven patients and corticosteroid dose
was reduced by 56% [240].
In 2013, Cipriani et al. reported on 11 patients with refractory
AOSD treated with 8 mg/kg tocilizumab monthly during
12 months [241]. The patients responded rapidly and experienced
a sustained clinical remission over time during the treatment. The
median DAS 28 decreased from 5.62 at baseline to 1.61. Remissions
of fever and improvements of systemic symptoms were observed
in the eight patients with such symptoms. The beneﬁcial effect of
tocilizumab seemed preserved after 6 months of treatment cessa-
tion. Very recent results on 15 Israeli tocilizumab-treated refracto-
ry AOSD patients seem to conﬁrm these data [242]; at the end of a
16-month mean follow-up, only two patients suffered from persis-
tent arthralgia whereas a single patient had to be switched to
canakinumab to control a RHL. Interestingly, one patient suffering
from secondary amyloidosis with proteinuria up to 2 g/24 h
showed a complete resolution of proteinuria after 6 months of
tocilizumab.Non-steroidal anti-inflammator
during diagnost
Confirmed A
(Yamagushi and Fautrel cri
Corticosteroids 0.8
Steroid-sparing treatment: Meth
To consider early whe
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Fig. 2. Proposal for a therapeutic stratMoreover, a randomized placebo-controlled trial demonstrated the
efﬁcacy of tocilizumab in the pediatric onset of the disease in which
85% of the children with severe persistent SOJIA met the composite pri-
mary end point (ACR Pedi 30 improvement in three out of six variables)
vs. 24% in the placebo group [243].
Overall, the literature reported on 40 patients with refractory AOSD
treated with tocilizumab. Beneﬁcial effects were better documented
with the chronic arthritis pattern of the disease but tocilizumab seems
effective on the accompanying systemic symptoms too. As anakinra,
tocilizumab showed a marked corticosteroid-sparing effect and a good
safety proﬁle. A French nationwide registry is currently built to collect
additional information on the long-term efﬁcacy and tolerance of
tocilizumab in AOSD in clinical practice.
5.5.4. Proposal for a therapeutic strategy in AOSD
According to the above data, we propose a therapeutic strategy for
AOSD (summarized in Fig. 2). Corticosteroids are the ﬁrst-line treat-
ment for inducing remission. Then, introduction ofmethotrexate shouldy drugs (indomethacine)
ic workup
OSD
teria could be helpful)
 - 1 mg/kg/day
otrexate 7.5 - 20 mg/week
n patients show:
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718 M. Gerfaud-Valentin et al. / Autoimmunity Reviews 13 (2014) 708–722not bedelayedwhen the patient exhibits theﬁrst signs or predictive fac-
tors of steroid-dependence. In the case of refractory AOSD, the chronic
arthritis should be ﬁrst treated with tocilizumab or inﬂiximab whereas
a systemic pattern should be treated with anakinra. Further studies
are required to see whether an earlier administration of anakinra or
tocilizumab is more beneﬁcial.
Take-home messages
• Recent insights into the pathophysiology of AOSD categorized it as a
‘complex’ autoinﬂammatory disorder and put it at the crossroads of
autoinﬂammatory and autoimmune diseases.
• According to the clinical presentation of the disease at diagnosis, two
phenotypes may be distinguished: i) a highly symptomatic, systemic
and feverish one which would evolve into a systemic pattern; ii) a
more indolent one with arthritis in the foreground and poor systemic
symptomatology whichwould evolve into a chronic articular pattern.
• Despite life-threatening complications such as RHL, the prognosis of
AOSD remains good and the mortality rate remains very low.
• Corticosteroids (0.8–1 mg/kg/d) and low-dose methotrexate is the
mainstay of AOSD treatment.
• TNFα-blockers (mainly inﬂiximab) could be interesting in chronic
polyarticular refractory AOSD.
• Anakinra seems to be an effective, well tolerated, and steroid-sparing,
but only a suspensive treatment in refractory systemic AOSD.
• Inhibiting the IL-6 pathway with tocilizumab seems efﬁcient in refrac-
tory AOSD with active arthritis.Acknowledgements
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